2 days Ago By ABMN Staff
Dynavax Technologies Co. ( NASDAQ:DVAX – Get Free Report ) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 16,780,000 shares, a decline of 6.
3% from the November 30th total of 17,900,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the short-interest ratio is currently 8.0 days.
Wall Street Analysts Forecast Growth Separately, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th. Check Out Our Latest Stock Report on Dynavax Technologies Dynavax Technologies Stock Performance Institutional Inflows and Outflows Several large investors have recently modified their holdings of DVAX.
GAMMA Investing LLC increased its position in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the last quarter.
US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares during the period.
Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth $45,000. Nisa Investment Advisors LLC raised its position in shares of Dynavax Technologies by 44.6% in the 3rd quarter.
Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in Dynavax Technologies in the third quarter valued at $89,000. 96.
96% of the stock is currently owned by hedge funds and other institutional investors. About Dynavax Technologies ( Get Free Report ) Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter ..
